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Antibacterial activityAbstract A series of novel (isopropylidene) uridine-[1,2,3]triazole hybrids (3a–3n) were efficiently
synthesized via the copper-catalyzed azide–alkyne cycloaddition (CuAAC) from N-propargyl 20,30-
O-(isopropylidene) uridine with different aryl azides. All the synthesized compounds were screened
for their in vitro anticancer and antibacterial activities. The anticancer activity results revealed that
compounds 3d and 3f have registered equipotent activity against MCF-7 and 3n has shown excellent
activity against HeLa in comparison with the standard drug Cisplatin. Remaining compounds have
shown moderate to good anticancer activity against MCF-7 and HeLa cell lines. The antibacterial
activity screening results revealed that, compounds 3b and 3n have shown excellent inhibition
against Escherichia coli and Bacillus subtilis, 3d against Proteus vulgaris, 3k against Staphylococcus
aureus and 3l against S. aureus and B. subtilis have shown equipotent activity in comparison with
the standard drug Streptomycin.
 2015 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nucleoside and their derivatives have emerged as molecules
with potentially useful therapeutic properties that have gainedconsiderable attention from both synthetic and medicinal
chemists due to their versatile biological activities in various
therapeutic areas. Zidovudine (30-azido-30-deoxythymidine)
was the first U.S. government-approved drug for the treatment
of HIV, marketed under the brand name Retrovir (Fig 1).
Uridine derivatives are currently used as anti influenza drugs
[1]. Over the past few years, several derivatives of the nucleo-
sides are known to possess antimicrobial [2], anticancer [3],
anti-inflammatory [4] and antiviral activities [5–8].
On the other hand, 1,2,3-triazole derivatives are known to
exhibit significant biological activities such as antimicrobial
[9,10], anticancer [11], antioxidant [12] anti-HIV [13],hybrids,
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Figure 1 Some of the uridine core containing biologically active
agents.
2 R.kumar Thatipamula et al.anti-inflammatory [14], antiprotozoal [15], anticonvulsant [16],
antihistamine [17] and anti-tubercular properties [18]. Such
compounds have also been reported as b3-selective adrenergic
receptor agonists [19], kinase inhibitors [20] and other enzyme
inhibitors [21].
In continuation of our research toward the synthesis of
biologically potent heterocyclic compounds [22,23], herein,
we report the synthesis of Nucleoside (uridine) based 1,2,
3-triazole derivatives by using the Cu (I) Catalyzed Azide
Alkyne Cyclization (CuAAC) reaction and their in vitro anti-
cancer and anti bacterial activities.
2. Experimental section
2.1. General
Copper (I) iodide and propargyl bromide were purchased from
Sigma–Aldrich and Cs2CO3 was purchased from S.D. Fine
Chemicals Limited. Thin-layer chromatography (TLC) was
performed using Merck silica gel 60 F254 precoated plates
(0.25 mm). Elemental analysis was performed on PerkinElmer
2400 Series II CHNS/O elemental analyzer. Melting points
were determined using a Cintex apparatus and were uncor-
rected. FTIR spectra were recorded using a Bruker spectrom-
eter and are reported in the frequency of absorption (cm1).
NMR (1H & 13C) spectra were recorded on 300 and 75 MHz
instruments and CDCl3 was used as solvent.
1H NMR spectra
were reported relative to Me4Si (d 0.0 ppm). Coupling constant
(J) values are presented in Hertz and spin multiples are given
as s (singlet), d (doublet), t (triplet), dd (doublets of doublet)
and m (multiplet). Mass spectral measurements were carried
out by EI method on a Jeol JMC-300 spectrometer at 70 eV.
2.2. Synthesis
2.2.1. Synthesis of 20,30-O-(1-Methylethylidene)-3-(2-propyn-1-
yl)uridine (2)
To a stirred solution of 20,30-O-(1-Methylethylidene)uridine
(5 g, 17.60 mmol) in acetonitrile (100 mL) were added propar-
gyl bromide (2.44 mL, 22.00 mmol) and cesium carbonate
(5.72 g, 17.60 mmol) and stirred at room temperature for
30 min. Then, the reaction mixture was filtered and concen-
trated under reduced pressure to afford crude compound.
The crude was diluted with H2O (50 mL) and extracted with
CHCl3 (3  50 mL). The combined organic layer was
washed with brine, dried over Na2SO4 and the resulted
residue was purified by column chromatography (SiO2, 2%Please cite this article in press as: R.k. Thatipamula et al., Synthesis, anticancer and
Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2015.12.00MeOH–CHCl3) to afford (4.48 g, 79 ± 1%) 2
0,30-O-(1-Methy
lethylidene)-3-(2-propyn-1-yl)uridine (2).
2.2.2. General procedure for synthesis of 1,4-disubstituted 1,2,3-
triazole derivatives (3a-3n)
To a solution of aryl amine (ArNH2, 1 mmol, 1.2 eq) in conc.
HCl (5 ml) was added an aqueous solution of NaNO2 (3 eq)
and stirred for 30 min at 0–5 C. Then, an aqueous solution
of NaN3 (1.5 eq) was added slowly at 0–5 C and stirred for
another 30 min. After completion of the reaction by TLC anal-
ysis, the crude mixture containing the azido derivative was
added to a mixture of compound-2 (1 eq) and CuI (5 mol%)
in THF and the reaction mixture was stirred at room temper-
ature for 6–12 h. The solvent was removed and the resulted
residue was dissolved in CH2Cl2, washed with water
(3  20 mL), dried over Na2SO4 and evaporated to afford
the crude compounds. The crude compounds were purified
by column chromatography using silica gel (100–200 mesh)
and 2% MeOH–CHCl3 system as an eluent to afford 1,2,3-
triazole derivatives (3a–3n) in good yields.
2.3. Spectral data
2.3.1. 20,30-O-(1-Methylethylidene)-3-(2-propyn-1-yl)uridine
(2)
White solid. Yield: 65%. mp = 93 C. IR (KBr) tmax/cm1:
3471 (NH, amide), 3281 (CAH, alkyne), 3097 (CH, aromatic),
2989, 2939 (CH, Sp3CH), 2126 (C„C, alkyne), 1711
(CACOAC), 1666 (NACOAN), 1544 (C‚C, aromatic),
1273, 1157, 1109 (CAOAC, ether) and 1083 (CAOH, 1 alco-
hol). 1H NMR (300 MHz, CDCl3, d in ppm): 1.39 (s, 3H,
ACH3), 1.58 (s, 3H, ACH3), 2.45 (s, 1H, CH„C), 2.89 (br s,
1H, OH), 3.81 (dd, J= 12.0, 3.2 Hz, 1H, H-50), 3.94 (dd,
J= 12.0, 2.5 Hz, 1 H, H-500), 4.33 (m, 1 H, H-40), 4.71 (s,
2H, CH2N), 4.94 (dd, J= 3.3, 6.2 Hz, 1H, H-3
0), 5.05 (dd,
J= 2.8, 6.5 Hz, 1 H, H-20), 5.63 (d, J= 2.8 Hz, 1 H, H-10),
5.83 (d, J= 8.0 Hz, 1 H, H-5), 7.38 (d, J= 7.9 Hz, 1 H,
H-6). MS (ESI) m/z: 323 [M+H].
2.3.2. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(4-methoxyphenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3a)
White solid. Yield: 87%. mp = 128 C, reaction time 8 h. IR
(KBr) tmax/cm
1: 3440 (OH, alcohol), 3092 (CH, aromatic),
2989 (CH, Sp3CH), 1700 (CACOAN), 1675 (NACOAN),
1582 (C‚C, aromatic), 1515 (NAN, triazole), 1211 (CAOAC,
3 ether), 1157, 1107 (CAOAC, ether), 1080 (CAOH, 1 alco-
hol), 850, 810, 771 (CAH aromatic bending), 1H NMR
(300 MHz, CDCl3, d in ppm): 1.36 (s, 3H, ACH3), 1.57
(s, 3H, ACH3), 2.84 (br s, 1H, OH), 3.71 (s, 3H, OCH3),
3.80 (dd, J= 12.0, 3.4 Hz, 1H, H-50), 3.93 (dd, J= 12.0,
2.6 Hz, 1H, H-500), 4.30–4.33 (m, 1H, H-40), 4.95 (dd,
J= 3.3, 6.2 Hz, 1H, H-30), 5.01 (dd, J= 2.8, 6.5 Hz, 1H, H-
20), 5.35 (m, 2H, CH2N), 5.61 (d, J= 2.8 Hz, 1H, H-10), 5.85
(d, J= 8.0 Hz, 1H, H-5), 7.02 (d, J= 9 Hz, 2H, Ar-H), 7.37
(d, J= 7.9 Hz, 1H, H-6), 7.62 (d, J= 9 Hz, 2H, Ar-H), 8.01
(s, 1H, triazole). 13C NMR (75 MHz, CDCl3, d in ppm): 25.1
(CH3), 27.1 (CH3), 33.5 (CH2N), 55.6 (OACH3), 62.5 (C-50),
80.2 (C-30), 83.5 (C-20), 86.8 (C-40), 96.6 (C-10), 102.1 (C-5),antibacterial evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids,
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Evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids 3113.1 (NACH‚C, triazole), 115.3 (ArAC-3, C-5), 119.3 (C
(CH3)2), 122.4 (ArAC-2, C-6), 129.1 (ArAC-1), 139.2 (Ar C),
140.9 (NACH‚C, triazole), 141.5 (C-6), 150.6 (C-2), 160.6
(ArAC-4), 163.7 (C-4). MS (ESI) m/z: 472 [M+H]+ (calc
471.17), Elemental analysis (%) found: C 55.58, H 5.44, N
14.89; calcd for C22H25N5O7: C 55.52, H 5.46, N 14.95.
2.3.3. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(naphthalene-1-yl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3b)
White solid. Yield: 70%. mp = 116 C. reaction time 9 h. IR
(KBr) tmax/cm
1: 3430 (OH, alcohol), 3083 (CH, aromatic),
2987 (CH, Sp3CH), 1717 (CACOAN), 1661 (NACOAN),
1575 (C‚C, aromatic), 1521 (N‚N, triazole), 1216, 1121
(CAOAC, ether), 1074 (CAOH, 1 alcohol), 880, 812, 771
(CAH aromatic bending). 1H NMR (300 MHz, CDCl3, d in
ppm): 1.35 (s, 3H, ACH3),1.58 (s, 3H, ACH3), 2.85 (br s,
1H, OH), 3.82 (dd, J= 12.0, 3.4 Hz, 1H, H-50), 3.94 (dd,
J= 12.0, 2.6 Hz, 1H, H-500), 4.30–4.33 (m, 1H, H-40), 4.99
(dd, J= 3.2, 6.5 Hz, 1H, H-30), 5.08 (dd, J= 2.7, 6.4 Hz,
1H, H-20), 5.39 (m, 2H, CH2N), 5.62 (d, J= 2.6 Hz, 1H, H-
10), 5.82 (d, J= 8.0 Hz, 1H, H-5), 7.42 (d, J= 7.9 Hz, 1H,
Ar), 7.50–7.60 (m, 4H, Ar), 7.62 (d, J= 8.0 Hz, 1H, H-6),
7.95 (d, J= 7.7 Hz, 1H, Ar), 8.00 (s, 1H, triazole), 8.02 (m,
1H, Ar). 13C NMR (75 MHz, CDCl3, d in ppm): 25.2 (CH3),
27.2 (CH3), 35.8 (CH2N), 62.6 (C-5
0), 80.5 (C-30), 84.0 (C-20),
87.9 (C-40), 95.1 (C-10), 102.0 (C-5), 116.0 (NACH‚C, tria-
zole), 120.1 (C(CH3)2), 125.1 (ArAC-1), 126.3 (ArAC-3,C-7,
C-8), 126.7 (ArAC-9), 128.4 (ArAC-4,C-6), 131.6 (ArAC-2),
133.7 (ArAC-5), 138.2 (ArAC-10) 140.6 (NACH‚C, triazole),
142.4 (C-6), 149.7 (C-2), 160.2 (ArAC-4) 163.5 (C-4). MS (ESI)
m/z: 514 [M+Na] (calc 491.18). Elemental analysis (%) found:
C 60.79, H 5.13, N 14.28; calcd for C25H25N5O6: C 60.90, H
5.15, N 14.32.
2.3.4. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(2-chloro-5-nitrophenyl)-1H-
1,2,3-triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-
dione (3c)
Pale yellow solid. Yield: 82%. mp = 142 C. reaction time 9 h.
IR (KBr) tmax/cm
1: 3429 (OH, alcohol), 3092 (CH, aro-
matic), 2989, 2932 (CH, Sp3CH), 1710 (CACOAN), 1665
(NACOAN), 1586 (C‚C, aromatic), 1534 (N‚N, triazole),
1350 (NAO aromatic NO2), 1218 (CAOAC, 3 ether), 1157,
1107 (CAOAC, ether), 1077 (CAOH, 1 alcohol), 880, 812,
772 (CAH aromatic bending). 1H NMR (300 MHz, CDCl3,
d in ppm):1.35 (s, 3H, ACH3), 1.59 (s, 3H, ACH3), 3.20 (br
s, 1H, OH), 3.83 (d, J= 10.8 Hz, 1H, H-50), 3.93 (d,
J= 11.1 Hz, 1H, H-500), 4.32 (m, 1H, H-40), 4.94 (dd,
J= 3.3, 6.4 Hz, 1H, H-30), 5.06 (dd, J= 2.7, 6.5 Hz, 1H, H-
20), 5.35 (m, 2H, CH2N), 5.70 (d, J= 2.8 Hz, 1H, H-10), 5.79
(d, J= 8.1 Hz, 1H, H-5), 7.52 (s, 1H, Ar), 7.80 (d,
J= 7.9 Hz, 1H, H-6), 8.20 (s, 1H, triazole), 8.25–8.55 (m,
2H, Ar). 13C NMR (75 MHz, CDCl3, d in ppm): 25.2 (CH3),
27.2 (CH3), 35.6 (CH2N), 62.6 (C-5
0), 80.3 (C-30), 83.8 (C-20),
87.0 (C-40), 96.8 (C-10), 102.0 (C-5), 114.2 (NACH‚C, tria-
zole), 120.0 (C(CH3)2), 120.3 (ArAC-6), 123.5 (ArAC-4),
125.9 (ArAC-3), 133.1 (ArAC-1), 135.1 (ArAC-5), 140.2
(ArAC-2), 140.7 (NACH‚C, triazole), 142.6 (C-6), 150.7Please cite this article in press as: R.k. Thatipamula et al., Synthesis, anticancer and
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520.11). Elemental analysis (%) found: C 48.36, H 4.06, N
16.23; calcd for C21H21ClN6O8: C 48.33, H 4.12, N 16.26.
2.3.5. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-({1-[5-fluoro-2-(hyroxymethyl)
phenyl]-1H-1,2,3-triazole-4-yl}methyl)-1,2,3,4-tetrahydro
pyrimidine-2,4-dione (3d)
White solid. Yield: 71%. mp = 162 C. reaction time 10 h. IR
(KBr) tmax/cm
1: 3440 (OH, alcohol), 3089 (CH, aromatic),
2983, 2937 (CH, Sp3CH), 1718 (CACOAC), 1661
(NACOAN), 1586 (C‚C, aromatic), 1525 (N‚N, triazole),
1216 (CAOAC, 3 ether), 1147, 1101 (CAOAC, ether), 1072
(CAOH, 1 alcohol), 881, 814, 770, (CAH aromatic bending).
1H NMR (300 MHz, CDCl3, d in ppm): 1.36 (s, 3H, ACH3),
1.59 (s, 3H, ACH3), 3.21 (br s, 1H, OH), 3.40–3.55 (br m,
1H, OH) 3.80 (dd, J= 12.0, 2.7 Hz, 1H, H-50), 3.92 (dd,
J= 11.9, 1.6 Hz, 1H, H-500), 4.31 (d, J= 2.4 Hz, 1H, H-40),
4.45 (s, 2H, CH2OH), 4.99 (dd, J= 2.8, 5.9 Hz, 1H, H-3
0),
5.08 (dd, J= 2.4, 6.1 Hz, 1H, H-20), 5.25 (m, 2H, CH2N),
5.64 (d, J= 2.2 Hz, 1H, H-10), 5.80 (d, J= 7.9 Hz, 1H, H-
5), 7.15–7.24 (m, 2H, Ar), 7.45 (d, J= 8.0 Hz, 1H, H-6),
7.55–7.62 (m, 1H, Ar) 8.06 (s, 1H, triazole). 13C NMR
(75 MHz, CDCl3, d in ppm): 25.0 (CH3), 27.1 (CH3), 35.6
(CH2N), 58.6 (ArACH2OH), 62.5 (C-50), 80.9 (C-30), 84.3
(C-20), 87.1 (C-40), 96.6 (C-10), 102.3 (C-5), 115.7 (ArAC-4,C-
6), 118.0 (NACH‚C, triazole), 121.0 (C(CH3)2), 126.9
(ArAC-1), 128.7 (ArAC-3), 136.3 (ArAC-2), 141.2
(NACH‚C, triazole), 142.6 (C-6), 150.5 (C-2), 159.3
(ArAC-5), 162.8 (C-4). MS (ESI) m/z: 490 [M+H] (calc
489.16). Elemental analysis (%) found: C 53.85, H 4.96, N
14.31; calcd for C22H24FN5O7: C 53.81, H 4.98, N 14.34.
2.3.6. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(3-nitrophenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3e)
Pale yellow solid. Yield; 85%. mp = 151 C. reaction time
10 h. IR (KBr) tmax/cm
1: 3430 (OH, alcohol), 3097 (CH, aro-
matic), 2986, 2938 (CH, Sp3CH), 1717 (CACOAC), 1661
(NACOAN), 1583 (C‚C, aromatic), 1521 (N‚N, triazole),
1347 (NAO aromatic NO2), 1222 (CAOAC, 3 ether), 1148,
1100 (CAOAC, ether), 1080 (CAOH, 1 alcohol), 885, 812,
770 (CAH aromatic bending). 1H NMR (300 MHz, CDCl3,
d in ppm): 1.35 (s, 3H, ACH3), 1.59 (s, 3H, ACH3), 2.91 (br
s, 1H, OH), 3.85 (d, J= 10.3 Hz, 1H, H-50), 3.95 (d,
J= 10.8 Hz, 1H, H-500), 4.30–4.32 (m, 1H, H-40), 5.00 (dd,
J= 3.1, 6.7 Hz, 1H, H-30), 5.09 (dd, J= 2.8, 6.4 Hz, 1H, H-
20), 5.30 (m, 2H, CH2N), 5.65 (d, J= 2.8 Hz, 1H, H-10), 5.82
(d, J= 7.8 Hz, 1H, H-5), 7.45 (d, J= 7.9 Hz, 1H, H-6),
7.70–7.80 (m, 1H, Ar), 8.15–8.30 (m, 3H, Ar), 8.60 (s, 1H, tri-
azole). 13C NMR (75 MHz, CDCl3, d in ppm): 25.1 (CH3),
26.3 (CH3), 38.3 (CH2N), 62.5 (C-5
0), 80.2 (C-30), 82.7 (C-20),
89.0 (C-40), 99.6 (C-10), 102.3 (C-5), 111.2 (ArAC-2), 118.1
(NACH‚C, triazole), 121.3 (C(CH3)2), 123.1 (ArAC-2),
125.2 (ArAC-4), 129.5 (ArAC-1,C-5), 136.3 (ArAC-6,C-3),
140.9 (NACH‚C, triazole), 142.5 (C-6), 149.6 (C-2), 164.8
(C-4). MS (ESI) m/z: 487 [M+H] (calc 486.15). Elemental
analysis (%) found: C 55.75, H 4.56, N 17.29; calcd for
C21H22N6O8: C 55.72, H 4.53, N 17.34.antibacterial evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids,
1
4 R.kumar Thatipamula et al.2.3.7. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(4-chlorophenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3f)
Pale yellow solid. Yield: 88%. mp = 156 C. reaction time 8 h.
IR (KBr) tmax/cm
1: 3437 (OH, alcohol), 3096 (CH, aro-
matic), 2972 (CH, Sp3CH), 1740 (CACOAC), 1658
(NACOAN), 1501 (N‚N, triazole), 1212 (CAOAC, 3 ether),
1157 (CAOAC, ether), 1088 (CAOH, 1 alcohol), 832, 809,
783 (CAH aromatic bending). 1H NMR (300 MHz, CDCl3,
d in ppm): 1.35 (s, 3H, ACH3), 1.59 (s, 3H, ACH3), 2.95 (br
s, 1H, OH), 3.82 (d, J= 11.1 Hz, 1H, H-50), 3.95 (d,
J= 10.9 Hz, 1H, H-500), 4.31 (d, J= 2.4 Hz, 1H, H-40), 4.98
(dd, J= 3.0, 5.9 Hz, 1H, H-30), 5.02 (dd, J= 2.9, 6.0 Hz,
1H, H-20), 5.30 (m, 2H, CH2N), 5.62 (d, J= 2.1 Hz, 1H,
H-10), 5.79 (d, J= 7.9 Hz, 1H, H-5), 7.44 (d, J= 7.9 Hz, 1H,
H-6), 7.49 (d, J= 8.7 Hz, 2H, Ar), 7.68 (d, J= 8.7 Hz, 2H,
Ar), 8.05 (s, 1H, triazole). 13C NMR (75 MHz, CDCl3, d in
ppm): 25.0 (CH3), 26.0 (CH3), 41.5 (CH2N), 63.0 (C-5
0), 80.6
(C-30), 83.8 (C-20), 87.4 (C-40), 98.3 (C-10), 102.4 (C-5), 118.1
(NACH‚C, triazole), 120.2 (C(CH3)2), 123.2 (ArAC-2,C-6),
128.7 (ArAC-3,C-5), 134.3 (ArAC-4), 134.9 (ArAC-1), 141.2
(NACH‚C, triazole), 141.9 (C-6), 150.3 (C-2), 163.4 (C-4).
MS (ESI) m/z: 498 [M+Na] (calc 475.12). Elemental analysis
(%) found: C 54.70, H 4.72, N 14.78; calcd for C21H22ClN5O6:
C 54.68, H 4.71, N 14.80.
2.3.8. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(4-methylphenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3g)
White solid. Yield: 85%. mp = 123 C. reaction time 10 h. IR
(KBr) tmax/cm
1: 3429 (OH, alcohol), 3092 (CH, aromatic),
2989, 2932 (CH, Sp3CH), 1710 (CACOAC), 1665
(NACOAN), 1586 (C‚C, aromatic), 1534 (N‚N, triazole),
1218, 1157 (CAOAC, ether), 1077 (CAOH, 1 alcohol), 771,
875, 809 (CAH aromatic bending). 1H NMR (300 MHz,
CDCl3, d in ppm): 1.33 (s, 3H, ACH3), 1.58 (s, 3H, ACH3),
2.30 (s, 3H, CH3), 3.21 (br s, 1H, OH), 3.81 (d, J= 10.1 Hz,
1H, H-50), 3.92 (d, J= 10.3 Hz, 1H, H-500), 4.25–4.35 (m,
1H, H-40), 4.97 (dd, J= 3.0, 6.2 Hz, 1H, H-30), 5.05 (dd,
J= 3.2, 6.4 Hz, 1H, H-20), 5.28 (m, 2H, CH2N), 5.71 (d,
J= 1.8 Hz, 1H, H-10), 5.81 (d, J= 8.1 Hz, 1H, H-5), 7.48
(d, J= 8.1 Hz, 2H, Ar), 7.61 (d, J= 8.1 Hz, 2H, Ar), 7.80
(d, J= 7.8 Hz, 1H, H-6) 8.12 (s, 1H, triazole). 13C NMR
(75 MHz, CDCl3, d in ppm): 22.8 (ArACH3), 25.1 (CH3),
26.6 (CH3), 38.2 (CH2N), 61.4 (C-5
0), 81.3 (C-30), 83.9 (C-20),
89.3 (C-40), 99.6 (C-10), 103.4 (C-5), 119.3 (NACH‚C, tria-
zole), 123.4 (C(CH3)2), 129.3 (ArAC-3, C-5), 132.1 (ArAC-
1), 135.3 (ArAC-2, C-6), 136.8 (ArAC-4), 143.1 (NACH‚C,
triazole), 145.2 (C-6), 151.8 (C-2), 163.7 (C-4). MS (ESI)
m/z: 456 [M+H] (calc 455.18). Elemental analysis (%) found:
C 58.11, H 5.53, N 15.39; calcd for C22H25N5O6: C 58.14, H
5.56, N 15.41.
2.3.9. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(4-nitrophenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3h)
Pale yellow solid. Yield: 86%. mp = 168 C. reaction time
12 h. IR (KBr) tmax/cm
1: 3427 (OH, alcohol), 3089 (CH,Please cite this article in press as: R.k. Thatipamula et al., Synthesis, anticancer and
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(NACOAN), 1599 (C‚C, aromatic), 1526 (N‚N, triazole),
1219, 1157 (CAOAC, ether), 1082 (CAOH, 1 alcohol), 855,
808, 772 (CAH aromatic bending). 1H NMR (300 MHz,
CDCl3, d in ppm): 1.35 (s, 3H, ACH3), 1.59 (s, 3H, ACH3),
2.93 (br s, 1H, OH), 3.84 (d, J= 10.4 Hz, 1H, H-50), 3.94 (d,
J= 11.2 Hz, 1H, H-500), 4.31 (d, J= 2.7 Hz, 1H, H-40), 4.95
(dd, J= 3.1, 6.7 Hz, 1H, H-30), 5.04 (dd, J= 2.8, 6.4 Hz,
1H, H-20), 5.35 (m, 2H, CH2N), 5.64 (d, J= 2.8 Hz, 1H,
H-10), 5.81 (d, J= 8.1 Hz, 1H, H-5), 7.48 (d, J= 8.1 Hz, 1H,
H-6), 7.61 (d, J= 8.2 Hz, 2H, Ar), 8.33 (d, J= 8.2 Hz, 2H,
Ar), 8.20 (s, 1H, triazole). 13C NMR (75 MHz, CDCl3, d in
ppm): 25.2 (CH3), 27.2 (CH3), 35.6 (CH2N), 62.6 (C-5
0), 80.3
(C-30), 83.9 (C-20), 86.9 (C-40), 96.4 (C-10), 101.9 (C-5), 114.3
(NACH‚C, triazole), 120.5 (C(CH3)2), 121.8 (ArAC-2,C-6)-,
125.4 (ArAC-3,C-5), 140.9 (NACH‚C, triazole), 142.1
(ArAC-1) 144.2 (C-6), 147.1 (ArAC-4), 150.7, (C-2), 162.0
(C-4); MS (ESI) m/z: 487 [M+H] (calc 486.15). Elemental
analysis (%) found: C 55.75, H 4.58, N 17.32; calcd for
C21H22N6O8: C 55.73, H 4.59, N 17.34.
2.3.10. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(2-methylphenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3i)
White solid. Yield: 80% .mp = 113 C. reaction time 11 h. IR
(KBr) tmax/cm
1: 3429 (OH, alcohol), 3092 (CH, aromatic),
2989, 2932 (CH, Sp3CH), 1710 (CACOAC), 1665
(NACOAN), 1586 (C‚C, aromatic), 1534 (N‚N, triazole),
1212 (CAOAC, 3 ether), 1155, 1107 (CAOAC, ether), 1081
(CAOH, 1 alcohol), 881, 812, 789 (CAH aromatic bending).
1H NMR (300 MHz, CDCl3, d in ppm): 1.32 (s, 3H, ACH3),
1.55 (s, 3H, ACH3), 2.34 (s, 3H, CH3), 2.91 (br s, 1H, OH),
3.71 (d, J= 10.2 Hz, 1H, H-50), 3.91 (d, J= 10.0 Hz, 1H,
H-500), 4.29–4.35 (m, 1H, H-40), 4.95 (dd, J= 2.7, 5.9 Hz,
1H, H-30), 5.05 (dd, J= 3.0, 6.1 Hz, 1H, H-20), 5.28 (m, 2H,
CH2N), 5.65 (d, J= 2.3 Hz, 1H, H-1
0), 5.82 (d, J= 8.1 Hz,
1H, H-5), 7.49 (d, J= 7.8 Hz, 1H, H-6), 7.49–7.56 (m, 4H,
Ar), 8.10 (s, 1H, triazole). 13C NMR (75 MHz, CDCl3, d in
ppm): 22.1 (ArACH3), 25.3 (CH3), 27.2 (CH3), 38.1 (CH2N),
63.1 (C-50), 81.2 (C-30), 83.3 (C-20), 88.5 (C-40), 96.6 (C-10),
102.3 (C-5), 114.2 (NACH‚C, triazole), 120.6 (C(CH3)2),
122.1 (ArAC-6), 125.3 (ArAC-5), 127.3 (Ar-C-1), 131.2
(ArAC-3,C-4), 138.8 (ArAC-2), 139.1 (NACH‚AC, triazole),
142.2 (C-6), 149.8 (C-2), 162.3 (C-4); MS (ESI) m/z: 456 [M
+H] (calc 455.18). Elemental analysis (%) found: C 58.11, H
5.45, N 15.39; calcd for C22H25N5O6: C 58.13, H 5.48, N 15.42.
2.3.11. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-[(1-phenyl-1H-1,2,3-triazole-4-yl)
methyl]-1,2,3,4-tetrahydropyrimidine-2,4-dione (3j)
White solid. Yield: 85%. mp = 119 C. reaction time 6 h. IR
(KBr) tmax/cm
1: 3462 (OH, alcohol), 3092 (CH, aromatic),
2989, 2932 (CH, Sp3CH), 1710 (CACOAC), 1665
(NACOAN), 1586 (C‚C, aromatic), 1534 (N‚N, triazole),
1218, 1157 (CAOAC, ether), 1081 (CAOH, 1 alcohol), 875,
810, 783 (CAH aromatic bending). 1HANMR (300 MHz,
CDCl3, d in ppm): 1.37 (s, 3H, ACH3), 1.58 (s, 3H, ACH3),
2.98 (br s, 1H, OH), 3.82 (d, J= 10.2 Hz, 1H, H-50), 3.95 (d,
J= 10.0 Hz, 1H, H-500), 4.31 (m, 1H, H-40), 4.96 (dd,
J= 3.2, 6.4 Hz, 1H, H-30), 5.02 (dd, J= 3.1, 6.1 Hz, 1H,antibacterial evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids,
1
Evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids 5H-20), 5.25 (m, 2H, CH2N), 5.60 (d, J= 2.8 Hz, 1H, H-10),
5.81 (d, J= 8.0 Hz, 1H, H-5), 7.45 (d, J= 8.0 Hz, 1H, H-6),
7.50 (m, 2H, Ar), 7.67 (m, 3H, Ar), 8.05 (s, 1H, triazole).
13C NMR (75 MHz, CDCl3, d in ppm): 25.1 (CH3), 27.3
(CH3), 36.4 (CH2N), 62.8 (C-5
0), 81.0 (C-30), 84.3 (C-20), 88.4
(C-40), 98.5 (C-10), 102.2 (C-5), 118.2 (NACH‚C, triazole),
121.3 (C(CH3)2), 122.4 (ArAC-2, C-6), 128.1 (ArAC-3, C-5),
129.3 (ArAC-4), 136.5 (ArAC-1), 140.1 (NACH‚C, triazole),
143.2 (C-6), 149.3 (C-2), 164.2 (C-4). MS (ESI) m/z: 442 [M
+H] (calc 441.16). Elemental analysis (%) found: C 57.19, H
5.15, N 15.88; calcd for C21H23N5O6: C 57.21, H 5.12, N 15.91.
2.3.12. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(3-chlorophenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3k)
Pale yellow solid. Yield: 76%. mp = 141 C. reaction time
10 h. IR (KBr) tmax/cm
1: 3466 (OH, alcohol), 3052 (CH, aro-
matic), 2972 (CH, Sp3CH), 1740 (CACOAC), 1656
(NACOAN), 1594 (C‚C, aromatic), 1534 (N‚N, triazole),
1212, 1157 (CAOAC, ether), 1077 (CAOH, 1 alcohol), 855,
806, 786 (CAH aromatic bending). 1H NMR (300 MHz,
CDCl3, d in ppm): 1.35 (s, 3H, ACH3), 1.59 (s, 3H, ACH3),
2.90 (br s, 1H, OH), 3.82 (dd, J= 12.0, 3.3 Hz, 1H, H-50),
3.94 (dd, J= 12.0, 2.4 Hz, 1H, H-500), 4.30–4.32 (m, 1H, H-
40), 4.97 (dd, J= 3.3, 6.4 Hz, 1H, H-30), 5.07 (dd, J= 2.7,
6.2 Hz, 1H, H-20), 5.30 (m, 2H, CH2N), 5.62 (d, J= 2.5 Hz,
1H, H-10), 5.82 (d, J= 8.0 Hz, 1H, H-5), 7.37–7.46 (m, 3H,
Ar), 7.62 (d, J= 8.3 Hz, 1H, H-6), 7.75–7.78 (m, 1H, Ar),
8.06 (s, 1H, triazole). 13C NMR (75 MHz, CDCl3, d in ppm):
25.8 (CH3), 27.6 (CH3), 36.2 (CH2N), 63.4 (C-5
0), 80.5 (C-
30), 85.2 (C-20), 88.4 (C-40), 97.5 (C-10), 102.4 (C-5), 112.2
(NACH‚C, triazole), 120.3 (C(CH3)2), 125.1 (ArAC-2),
127.6 (ArAC-6), 128.3 (ArAC-4), 132.1 (ArAC-5), 134.7
(ArAC-3), 138.2 (ArAC-1), 140.0 (NACH‚C, triazole),
141.8 (C-6), 149.6 (C-2), 163.2 (C-4). MS (ESI) m/z: 498 [M
+Na] (calc 475.12). Elemental analysis (%) found: C 53.00,
H 4.66, N 14.72; calcd for C21H22ClN5O6: C 53.08, H 4.72,
N 14.80.
2.3.13. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(3,5-dichlorophenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3l)
White solid. Yield. 79%. mp = 138 C. reaction time 12 h. IR
(KBr) tmax/cm
1: 3499 (OH, alcohol), 3086 (CH, aromatic),
3000 (CH, Sp3CH), 1740 (CACOAC), 1663 (NACOAN),
1587 (N‚N, triazole), 1214, 1104 (CAOAC, ether), 1084
(CAOH, 1 alcohol), 852, 814, 766 (CAH aromatic bending).
1H NMR (300 MHz, CDCl3, d in ppm): 1.36 (s, 3H, ACH3),
1.58 (s, 3H, ACH3), 2.65 (br s, 1H, OH), 3.82 (dd, J= 12.0,
3.2 Hz, 1H, H-50), 3.95 (dd, J= 12.0, 2.4 Hz, 1H, H-500),
4.31 (d, J= 2.7 Hz, 1H, H-40), 5.00 (dd, J= 3.3, 6.2 Hz,
1H, H-30), 5.05 (dd, J= 2.7, 6.4 Hz, 1H, H-20), 5.30 (m, 2H,
CH2N), 5.60 (d, J= 2.7 Hz, 1H, H-1
0), 5.82 (d, J= 8.0 Hz,
1H, H-5), 7.38 (d, J= 7.9 Hz, 1H, H-6), 7.42 (s, 1H, Ar),
7.67–7.70 (m, 2H, Ar), 8.05 (s, 1H, triazole). 13C NMR
(75 MHz, CDCl3, d in ppm): 25.3 (CH3), 27.2 (CH3), 35.9
(CH2N), 64.0 (C-5
0), 81.5 (C-30), 85.0 (C-20), 88.4 (C-40), 96.5
(C-10), 101.5 (C-5), 117.3 (NACH‚C, triazole), 121.1 (CPlease cite this article in press as: R.k. Thatipamula et al., Synthesis, anticancer and
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1), 136.3 (ArAC-3,C-5), 140.0 (NACH‚C, triazole), 141.8
(C-6), 150.6 (C-2), 162.4 (C-4). MS (ESI) m/z: 510 [M+H]
(calc 509.08); Elemental analysis (%) found: C 49.42, H 4.19,
N 13.78; calcd for C21H21Cl2N5O6: C 49.31, H 4.20, N 13.80.2.3.14. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(4-bromophenyl)-1H-1,2,3-
triazole-4-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3m)
Pale brown solid. Yield. 84%. mp = 172 C. reaction time
10 h. IR (KBr) tmax/cm
1: 3465 (OH, alcohol), 3083 (CH, aro-
matic), 2997, 2971 (CH, Sp3CH), 1740 (CACOAC), 1660
(NACOAN), 1571 (N‚N, triazole), 1212, 1157 (CAOAC,
ether), 1076 (CAOH, 1 alcohol), 856, 808, 752 (CAH aro-
matic bending).1H NMR (300 MHz, CDCl3, d in ppm): 1.35
(s, 3H, ACH3), 1.59 (s, 3H, ACH3), 2.89 (br s, 1H, OH),
3.82 (d, J= 10.3 Hz, 1H, H-50), 3.95 (d, J= 10.9 Hz, 1H,
H-500), 4.30–4.33 (m, 1H, H-40), 4.98 (dd, J= 3.1, 6.0 Hz,
1H, H-30), 5.09 (dd, J= 2.8, 6.2 Hz, 1H, H-20), 5.28 (s, 2H,
CH2N), 5.63 (d, J= 2.7 Hz, 1H, H-1
0), 5.82 (d, J= 8.0 Hz,
1H, H-5), 7.43 (d, J= 7.9 Hz, 1H, H-6), 7.51 (d, J= 8.7 Hz,
2H, Ar), 7.63 (d, J= 8.7 Hz, 2H, Ar), 8.05 (s, 1H, triazole).
13C NMR (75 MHz, CDCl3, d in ppm): 25.1 (CH3), 27.2
(CH3), 36.5 (CH2N), 62.3 (C-5
0), 81.5 (C-30), 83.8 (C-20), 88.4
(C-40), 97.6 (C-10), 102.5 (C-5), 118.3 (NACH‚C, triazole),
119.5 (C(CH3)2), 123.4 (ArAC-4), 129.2 (ArAC-2,C-6), 132.4
(ArAC-3,C-5), 135.3 (ArAC-1), 140.1 (NACH‚C, triazole),
142.0 (C-6), 150.1 (C-2), 164.1 (C-4). MS (ESI) m/z: 520 [M
+H] (calc 519.07); Elemental analysis (%) found: C 48.37, H
4.36, N 13.46; calcd for C21H22BrN5O6: C 48.36, H 4.35, N
13.50.2.3.15. 1-[6-(hydroxymethyl)-2,2-dimethyl-tetrahydro-2H-furo
[3,4-d][1,3]dioxol-4-yl]-3-{[1-(2,6-dibromo-4-fluorophenyl)-
1H-1,2,3-triazole-4-yl]methyl}-1,2,3,4-tetrahydro pyrimidine-
2,4-dione (3n)
Brown solid. Yield: 86%. mp = 161 C. reaction time 8 h; IR
(KBr) tmax/cm
1 3429 (OH, alcohol), 3092 (CH, aromatic),
2989, 2932 (CH, Sp3CH), 1710 (CACOAC), 1665
(NACOAN), 1586 (C‚C, aromatic), 1534 (N‚N, triazole),
1218 (CAOAC, 3 ether), 1157, 1107 (CAOAC, ether), 1077
(CAOH, 1 alcohol), 879, 809, 785 (CAH aromatic bending).
1H NMR (300 MHz, CDCl3, d in ppm): 1.35 (s, 3H, ACH3),
1.59 (s, 3H, ACH3), 2.79 (br s, 1H, OH), 3.85 (d,
J= 11.2 Hz, 1H, H-50), 3.94 (d, J= 10.8 Hz, 1H, H-500),
4.32 (d, J= 1.8 Hz, 1H, H-40), 4.99 (dd, J= 3.1, 6.0 Hz,
1H, H-30), 5.06 (dd, J= 2.8, 6.2 Hz, 1H, H-20), 5.34 (s, 2H,
CH2N), 5.61 (d, J= 2.7 Hz, 1H, H-1
0), 5.83 (d, J= 8.0 Hz,
1H, H-5), 7.38 (d, J= 8.0 Hz, 1H, H-6), 7.43 (s, 2H, Ar),
8.06 (s, 1H, triazole). 13C NMR (75 MHz, CDCl3, d in ppm):
25.3 (CH3), 26.1 (CH3), 35.8 (CH2N), 61.6 (C-5
0), 81.8 (C-
30), 85.0 (C-20), 88.2 (C-40), 97.4 (C-10), 102.5 (C-5), 114.1
(NACH‚C, triazole), 119.4 (C(CH3)2), 121.3 (ArAC-3,C-5),
124.1 (ArAC-2,C-6), 132.4 (ArAC-1), 140.0 (NACH‚C, tria-
zole), 141.2 (C-6), 150.3 (C-2), 163.2 (C-4) 167.1 (ArAC-4).
MS (ESI) m/z: 616 [M+H] (calc 614.97); Elemental analysis
(%) found: C 40.76, H 3.27, N 11.45; calcd for C21H20Br2FN5-
O6: C 40.74, H 3.30, N 11.46.antibacterial evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids,
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The synthesized compounds were evaluated for their in vitro
anticancer activity against two different human cancer cell
lines, i.e. breast cancer cell line (MCF-7) and cervical carci-
noma cell line (HeLa). Cell viability in the presence of the test
samples were measured by the MTT-microcultured tetra-
zolium assay [27]. This assay is a quantitative colorimetric
method for the determination of cell viability. The assessed
parameter is the metabolic activity of viable cells. Metaboli-
cally active cells reduce the pale yellow tetrazolium salt
(MTT) to a dark blue water-insoluble formazan, which can
be directly quantified after solubilization with DMSO. The
absorbance of formazan directly correlates with the number
of viable cells. MCF-7 and HeLa cells were plated into a
96-well plate at a density of 1x104 cells/well. Cells were grown
overnight in the full medium and then switched to the low
serum media. DMSO was used as control. After 48 h of treat-
ment with different concentrations of test compounds, the cells
were incubated with MTT (2.5 mg/mL) in the CO2 chamber
for 2 h. The medium was then removed and 100 lL of DMSO
was added into each well to dissolve formazan crystals. After
thoroughly mixing, the plates were read at 570 nm for optical
density which is directly correlated with cell quantity. The
results were represented as percentage of viability. All the
experiments were carried out in triplicate. The response
parameter calculated was the IC50 value, which corresponds
to the concentration required for 50% inhibition of cell
viability.
2.5. Assay of in vitro antibacterial activity
The minimum inhibitory concentrations (MIC) of synthesized
compounds (3a–3n) were tested against Gram-positive organ-
isms such as Staphylococcus aureus (MTCC 96) and Bacillus
subtilis (MTCC 441) and gram negative bacteria Escherichia
coli (MTCC 443) and Proteus vulgaris (MTCC 1771) by the
broth dilution method recommended by the National Commit-
tee for Clinical Laboratory (NCCL) standards [28]. Serial dilu-
tions of the test compounds were performed at concentrations
ranging from 150 to 0.58 lg mL1 in a 200 mL culture medium
final volume. Afterward each well was seeded with a 50 lL
microbial suspension of 0.5 MacFarland density. In each test
a microbial culture control and a sterility control (negative)
were performed. The plates were incubated for 24 h at 37 C.
The lowest concentration which inhibited the visible microbial
growth was considered the MIC.N
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3.1. Chemistry
The synthetic route for the preparation of uridine derived
1,2,3-triazoles is depicted in Scheme 1. 20,30-O-(isopropylidene)
uridine was subjected to propargylation using propargyl bro-
mide in the presence of Cs2CO3 to yield (79 ± 1%) of the
compound-2 [24]. Aryl azides were synthesized from diazo-
nium salts of aryl amines and NaN3 [25]. Compounds (3a–
3n) were synthesized by the treatment of 20, 30-O-(isopropyli
dene)-3-(2-propyn-1-yl) uridine (2) with aryl azides in the pres-
ence of catalytic amount of CuI in THF at room temperature
[26]. 20,30-O-(isopropylidene) uridine was used instead of Uri-
dine to simplify the reaction. Uridine on direct alkylation
yielded only 20–25% N-propargyl product.
All the crude compounds were purified by column chro-
matography using silica gel (60–120 mesh) and 2% MeOH in
CHCl3 as eluent. The elemental analysis results were within
± 0.2% of the calculated values indicate the purity of com-
pounds. The structures of newly synthesized compounds were
confirmed by IR, 1H NMR, 13C NMR and Mass spectral data.
Frequency of absorption in the region of 1515–1587 cm1
(N‚N) in IR spectra, signal at 8.00–8.60 ppm (H-5 of triazole)
in 1H NMR spectra and two signals at 112.2–119.3 ppm
(NACH‚C,C-4) and 139.1–143.1 ppm (NACH‚C, C-5) in
13C NMR spectra confirmed the formation of the triazole ring.
Similarly, the molecular ion peak from the mass spectra and
elemental analyses data are further evidence for the formation
of the products.3.2. In vitro anticancer activity
The examination of anticancer activity results (Table 1)
revealed that, compound derived from 2-hydroxy methyl-5-
fluoro phenyl on the triazole ring, i.e., 3d has exhibited excel-
lent activity against MCF-7 (IC50: 11.34 lM) and good activity
against HeLa (IC50: 16.48 lM) when comparing with the stan-
dard drug Cisplatin. Compound derived from 4-chloro phenyl
on the triazole ring, i.e., 3f has exhibited excellent activity
against MCF-7 (IC50: 11.73 lM). Compound 3n, bearing 2,
6-dibromo-4-fluoro group on the triazole ring against Hela
(IC50:7.93 lM), 3b and 3c against MCF-7 (IC50:14.20 and
18.58 lM) have shown good activity. The remaining com-
pounds have exhibited moderate activity against both cancer
cell lines ranging from 20.21 to >200 lM.3
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Table 1 Inhibition values (IC50) of 1,2,3-triazole derivatives
(3a–3n) on human tumor cell lines MCF-7 and HeLa.
Entry Product MCF-7 (IC50) HeLa (IC50)
1 3a 52.33 55.99
2 3b 14.20 20.21
3 3c 18.58 54.95
4 3d 11.34 16.48
5 3e >200 >200
6 3f 11.73 51.88
7 3g >200 >200
8 3h 45.01 >200
9 3i 53.41 69.09
10 3j >200 >200
11 3k 49.17 24.85
12 3l 25.68 34.13
13 3m >200 50.66
14 3n 35.30 7.93
15 Cisplatin 11.44 7.28
Evaluation of novel (isopropylidene) uridine-[1,2,3]triazole hybrids 73.3. In vitro antibacterial activity
The minimum inhibitory concentrations (MIC) of synthesized
compounds (3a–3n) were tested against Gram-positive and
Gram negative bacteria. The antibacterial activity screening
results (Table 2) revealed that, compounds possessing the
napthyl group and 2, 6-dibromo-4-chloro phenyl group on
the triazole ring (3b and 3n) have shown excellent activity
against E. coli and B. Subtilis when comparing with the stan-
dard drug Streptomycin. Compound 3d against P. vulgaris,
3k against S. aureus, and compound 3l against S. aureus and
B. subtilis have shown promising antibacterial activity.
Structure–activity relationship of the compounds (3a–3n)
revealed that, the 1st position of the triazole ring bearing
napthyl (3b), 2-hydroxymethyl 5-fluoro phenyl (3d), 3-chloro
phenyl (3k), 3,5-dichloro phenyl (3l) and 2,6-dibromo-4-
fluoro phenyl (3n) were found to be potent antibacterial
agents and the compounds bearing 4-methoxy phenyl (3a)Table 2 The MIC of 1, 2, 3-triazole derivatives (3a–3n) on
different bacterial strains.
MIC (lg/ml)
Compound E. coli S. aureus P. vulgaris B. Subtilis
3a 75 37.5 9.37 >150
3b 2.343 >150 >150 4.687
3c >150 9.37 >150 18.75
3d >150 >150 4.687 >150
3e >150 >150 >150 >150
3f 37.5 75 >150 >150
3g >150 >150 >150 >150
3h >150 >150 >150 >150
3i 37.5 75 >150 >150
3j >150 >150 75 37.5
3k >150 2.343 >150 >150
3l >150 4.687 >150 2.343
3m >150 >150 >150 >150
3n 1.171 >150 >150 2.343
Streptomycin 6.25 6.25 3.125 6.25
Please cite this article in press as: R.k. Thatipamula et al., Synthesis, anticancer and
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antibacterial agents than the remaining compounds.
4. Conclusion
In summary, we have designed and synthesized a series of
novel 1, 2, 3-triazole clubbed uridine hybrids and evaluated
for their anticancer and antibacterial activities. Among the ser-
ies, compounds 3d and 3f have shown potent activity against
breast cancer cell line-MCF-7 and compound 3n has shown
excellent activity against cervical carcinoma cell line (HeLa)
than the standard drug Cisplatin. The active compounds can
be considered as future drug candidates for cancer therapy,
and by effecting a simple modification in the structure a new
potent analog can be generated that has desired anticancer
activity with good efficacy. Similarly, compounds 3b and 3n
have shown marked antibacterial activity against E. coli & B.
subtilis, 3d against S. aureus, 3k against S. aureus & B. subtilis
and 3l against P. vulgaris have shown very good antibacterial
activity.
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